Evidence Synthesis
BAL Pharmposted a 47.5% quarterly gross margin, accelerating from 5.83%.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 18 Sept 2026, 00:17
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
BAL Pharmposted a 47.5% quarterly gross margin, accelerating from 5.83%.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 47.5 % | 5.83 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 5.83 % | 2.16 | ▲ |
| REVENUE_GROWTH_YOY | 34.5 % | 446.2 | ▼ |
| PRICE_CHANGE_PERCENT | 1.115 % | — | - |
| DAILY_VOLUME | 39,586 shares | 70,900 | ▼ |
| CLOSE_PRICE | 102.46 INR | 101.33 | ▲ |